Sanofi hasn’t had much to brag about when it comes to new product launches in the 5 years since Chris Viehbacher took the helm of the pharma giant. While he’s tried, not always successfully, to reinvigorate R&D–buying Genzyme in the process–new therapies have added less than a billion euros a year to the top line, according to PMLive.

…read more

Source: Sanofi looks to Regeneron to salvage its R&D rep


0 No comments